Last reviewed 2026-05-25 · How we verify

VELNACRINE

Phase 2 active Small molecule

VELNACRINE is a velnacrine drug. It is currently in Phase 2 development.

VELNACRINE works by blocking the enzyme that breaks down a neurotransmitter called acetylcholine.

VELNACRINE is a small molecule drug that targets Acetylcholinesterase, a key enzyme involved in the breakdown of acetylcholine, a neurotransmitter. It is classified as a velnacrine drug, but its commercial status is unknown. Velnacrine's mechanism of action is to inhibit the activity of Acetylcholinesterase, thereby increasing the levels of acetylcholine in the brain. However, it is not FDA-approved for any indications, and its safety profile and pharmacokinetic properties are not well established. Further research is needed to determine its potential therapeutic applications and risks.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	VELNACRINE
Drug class	velnacrine
Target	Acetylcholinesterase, Acetylcholinesterase, Butyrylcholinesterase
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of acetylcholine like a messenger in your brain that helps with memory and learning. When Velnacrine blocks the enzyme that breaks it down, more of these messengers are available to help with these functions. This can potentially help people with conditions like Alzheimer's disease, but more research is needed to confirm its effectiveness and safety.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VELNACRINE CI brief — competitive landscape report
VELNACRINE updates RSS · CI watch RSS

Frequently asked questions about VELNACRINE

What is VELNACRINE?

VELNACRINE is a velnacrine drug.

How does VELNACRINE work?

VELNACRINE works by blocking the enzyme that breaks down a neurotransmitter called acetylcholine.

What drug class is VELNACRINE in?

VELNACRINE belongs to the velnacrine class. See all velnacrine drugs at /class/velnacrine.

What development phase is VELNACRINE in?

VELNACRINE is in Phase 2.

What does VELNACRINE target?

VELNACRINE targets Acetylcholinesterase, Acetylcholinesterase, Butyrylcholinesterase and is a velnacrine.

Drug class: All velnacrine drugs
Target: All drugs targeting Acetylcholinesterase, Acetylcholinesterase, Butyrylcholinesterase
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing